European Myeloma Network Provides Vaccine Recommendations for MM
Patients with myeloma should receive 2 doses of the trivalent or quadrivalent vaccine influenza vaccine and vaccinations should continue annually.
Oncology
CLL Diagnosis Preceded by Decades of Increased Infection Susceptibility
Infections often precede a formal diagnosis of CLL. Researchers found that antimicrobial use began to rise 6 years prior to CLL diagnosis.
Increased Risk of Mycobacterial Infection With Immune Checkpoint Inhibitors
Using FAERS, study researchers identified reported cases of tuberculosis and atypical mycobacterial infection in patients who received ICIs.
Understanding the Oncogenic Role of HIV in Burkitt Lymphoma
While the rate of certain HIV-linked non-Hodgkin lymphomas has declined since the introduction of ART, the incidence of Burkitt lymphoma has remained steady.
ASCO Issues Provisional Opinion Update on Hepatitis B Screening
ASCO recommends that patients with newly diagnosed cancer slated to receive systemic anticancer meds be tested for HBV by 3 tests prior to starting therapy.
Risk-Adapted Therapy Prevents Fungal Infections in Childhood Leukemia
Risk-adapted therapy effectively prevents fungal infections and reduces neurotoxicity in children with leukemia.
Methotrexate-Induced Acute Kidney Injuries in Patients with Hematologic Malignancies
Upon starting methotrexate treatment, LDH and albumin levels may be signals for AKIs in patients with hematologic malignancies.
Study Finds Vancomycin Increased Risk for Cytomegalovirus Reactivation After Hematopoietic Cell Transplant
A retrospective study of CMV-seropositive adults receiving allogeneic HCT and CMV-seronegative HLA-matched sibling donors found that vancomycin exposure before HCT increased the risk for CMV reactivation.
Timing of Bacterial Infection Eradication Therapy Affects Neoplasm Risk in Early Gastric Cancer
Prescription of Helicobacter pylori eradication therapy within 1 year of gastric cancer treatment reduces the risk of later metachronous lesion development.
Gardasil 9 Approved to Prevent Certain HPV-Related Head and Neck Cancers
The FDA has approved an expanded indication for Gardasil 9® (human papillomavirus 9-valent vaccine [HPV], recombinant; Merck) to include the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58 in patients aged 9 to 45 years.
-
Loading...
-
Loading...
Next post in Genitourinary
